Last year, the board voted to deem Enbrel “unaffordable,” setting up a months-long process of determining whether it should ...
New treatment approved for primary humoral immunodeficiency; eyedrops now available to improve near vision; Tremfya approval expanded to include pediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback